Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
To investigate anatomical responses and visual changes in cases of exudative age-related macular degeneration (AMD) with choroidal vascular hyperpermeability (CVH) that responded poorly to multiple ranibizumab injections and were treated with intravitreal aflibercept. Retrospective comparative study. Twenty-five consecutive patients attending the outpatient clinic of the University of Tokyo Hospital who showed an insufficient response to multiple intravitreal ranibizumab injections and were switched to intravitreal aflibercept injections between March and June 2013. All patients were treated with intravitreal aflibercept in a treat-and-extend regimen and followed up for at least 12 months. Presence or absence of CVH was determined by indocyanine green angiography. Changes of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months were compared between the CVH (+) AMD and CVH (-) AMD eyes. The improvement in logMAR BCVA at 12 months was larger in the CVH (-) AMD eyes than in the CVH (+) AMD eyes (-0.18 vs -0.026; P = 0.0089, t-test). The changes in CRT did not differ significantly between the groups (-122 ± 101 μm in the CVH (-) AMD eyes and -159 ± 118 μm in the CVH (+) AMD eyes; P = 0.44, t-test). The proportion of the eyes without intraretinal or subretinal fluid or hemorrhage was 88% in the CVH (-) AMD and 67% in the CVH (+) AMD (P = 0.21, t-test). Compared with AMD without CVH, AMD with CVH showed poorer visual gain resulting from intravitreal aflibercept treatment.